Abeona Therapeutics leitet klinische Phase-3-Schlüsselstudie zur Beurteilung der Gentherapie EB-101 bei rezessiver dystropher Epidermolysis bullosa (RDEB) ein
13. Januar 2020 15:32 ET
|
Abeona Therapeutics Inc.
Die Studie ist für die Rekrutierung geöffnet und das Patientenscreening ist an der Stanford University angelaufen Das Unternehmen erwartet die Behandlung des ersten Patienten im ersten Quartal 2020 ...
Abeona Therapeutics lance un essai clinique pivot de phase 3 évaluant la thérapie génique EB-101 pour l'épidermolyse bulleuse dystrophique récessive
13. Januar 2020 15:32 ET
|
Abeona Therapeutics Inc.
Les inscriptions à l'étude sont ouvertes et la sélection des patients est en cours à l'Université de Stanford La société s'attend à ce qu'un premier patient soit traité au cours du premier trimestre...
Abeona Therapeutics Initiates Pivotal Phase 3 Clinical Trial Evaluating EB-101 Gene Therapy for Recessive Dystrophic Epidermolysis Bullosa
13. Januar 2020 09:00 ET
|
Abeona Therapeutics Inc.
Study open for enrollment and patient screening underway at Stanford University Company expects first patient to be treated in the first quarter of 2020 EB-101 manufactured at Abeona facility in...
Abeona Announces Closing of $103.5 Million Underwritten Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
24. Dezember 2019 13:01 ET
|
Abeona Therapeutics Inc.
NEW YORK and CLEVELAND, Dec. 24, 2019 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced the closing of its underwritten...
Abeona Announces Pricing of Public Offering of Common Stock and Pre‑Funded Warrants
20. Dezember 2019 09:23 ET
|
Abeona Therapeutics Inc.
NEW YORK and CLEVELAND, Dec. 20, 2019 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced the pricing of its public...
Abeona Therapeutics Announces Public Offering of Common Stock and Pre Funded Warrants
19. Dezember 2019 17:20 ET
|
Abeona Therapeutics Inc.
NEW YORK and CLEVELAND, Dec. 19, 2019 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced that it intends to offer and...
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against PG&E Corporation, Twitter, Sealed Air, and Abeona Therapeutics and Encourages Investors to Contact the Firm
11. Dezember 2019 17:17 ET
|
Bragar Eagel & Squire
NEW YORK, Dec. 11, 2019 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder law firm, reminds investors that class action lawsuits have been commenced on behalf...
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Abeona, AZZ, Under Armour, and UP Fintech and Encourages Investors to Contact the Firm
04. Dezember 2019 17:00 ET
|
Bragar Eagel & Squire
NEW YORK, Dec. 04, 2019 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder law firm, reminds investors that class action lawsuits have been commenced on behalf...
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Sealed Air, Abeona, AZZ, and Under Armour and Encourages Investors to Contact the Firm
27. November 2019 15:00 ET
|
Bragar Eagel & Squire
NEW YORK, Nov. 27, 2019 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder law firm, reminds investors that class action lawsuits have been commenced on behalf...
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Zendesk, PG&E Corporation, Sealed Air, and Abeona and Encourages Investors to Contact the Firm
20. November 2019 17:46 ET
|
Bragar Eagel & Squire
NEW YORK, Nov. 20, 2019 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder law firm, reminds investors that class action lawsuits have been commenced on behalf...